

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

GUIDANCE EXECUTIVE (GE)

Consideration of consultation responses on review proposal

Review of TA47 Glycoprotein IIb/IIIa inhibitors in the treatment of acute coronary syndromes

This guidance was issued in September, 2002.

The review date for this guidance: A review of glycoproteins was considered during July 2007. It was decided (after consultation) that the existing guidance should be updated by the NICE clinical guideline on acute coronary syndromes. However, only part of the current guidance will be updated by the clinical guideline (sections 1.1 - 1.6). This review covers sections 1.7 and 1.8 of the guidance.

Background

At the GE meeting 23 March 2010 it was agreed we would consult on the review plans for this guidance. A four week consultation has been conducted with consultees and commentators and the responses are presented below.

Proposal put to consultees:	A review proposal indicating that the guidance should be transferred to the static list.
------------------------------------	---

GE is asked to consider the original proposal in the light of the comments received from consultees and commentators, together with any responses from the appraisal team. It is asked to agree on the final course of action for the review.

Recommendation post consultation:	The guidance should be transferred to the static list.
--	---

Respondent	Response to proposal	Details	Comment from Technology Appraisal
Eli Lilly (abciximab)	Agree		Comment noted. No action required.
British Cardiovascular Intervention Society	Agree	“Also agree that the guideline “Unstable angina and NSTEMI: the early management of unstable angina and non-ST segment elevation myocardial infarction” published in March 2010 has adequately updated the guidance and that no new information on this topic exists that should change these guidelines.”	Comment noted. No action required.
NHS Quality Improvement Scotland	No Comment		Comment noted. No action required.

No response received from:

Consultees	Commentators (no right to submit or appeal)
<p><u>Manufacturers/sponsors</u></p> <ul style="list-style-type: none"> • GlaxoSmithKline (eptifibatide) • Iroko (tirofiban) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Action Heart • Afiya Trust • Arrhythmia Association 	<p><u>General</u></p> <ul style="list-style-type: none"> ▪ Board of Community Health Councils in Wales ▪ British National Formulary ▪ Commissioning Support Appraisals Service ▪ Department of Health, Social Services and Public Safety for Northern Ireland ▪ Medicines and Healthcare products Regulatory Agency ▪ National Association of Primary Care

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • Black Health Agency • Blood Pressure Association • British Cardiac Patients Association • Cardiac Risk in the Young • Chinese National Healthy Living Centre • Counsel and Care • Equalities National Council • Heart Care Partnership (UK) • HEART UK • Muslim Council of Great Britain • Muslim Health Network • National Heart Forum • Network of Sikh Organisations • SADS UK • South Asian Health Foundation • Specialised Healthcare Alliance <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • British Association for Nursing in Cardiac Care • British Association for Services to the Elderly • British Association of Emergency Medicine • British Atherosclerosis Society • British Cardiovascular Intervention Society • British Cardiovascular Society • British Geriatrics Society • British Heart Foundation • British Nuclear Cardiology Society • British Society of Cardiac Radiology 	<ul style="list-style-type: none"> ▪ NHS Alliance ▪ NHS Commercial Medicines Unit ▪ NHS Confederation ▪ Public Health Wales NHS Trust ▪ Scottish Medicines Consortium <p><u>Comparator manufacturers</u></p> <ul style="list-style-type: none"> ▪ None <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Antithrombotic Trialists Collaboration • British Society for Cardiovascular Research • Cardiac and Cardiology Research Dept, Barts and The London • Cardiovascular Diseases Specialist Library • Cochrane Heart Group • Cochrane Peripheral Vascular Diseases Group • CODA • European Council for Cardiovascular Research • MRC Clinical Trials Unit • National Institute for Health Research • Policy Research Institute on Ageing and Ethnicity • Research Institute for the Care of Older People • Wellcome Trust <p><u>Assessment Group</u></p> <ul style="list-style-type: none"> ▪ National Institute for Health Research Health Technology Assessment Programme ▪ tbc

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • Primary Care Cardiovascular Society • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal Pharmaceutical Society • Royal Society of Medicine • Society for Cardiological Science and Technology • Society of Cardiothoracic Surgeons • United Kingdom Clinical Pharmacy Association • Vascular Society <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health • NHS Barnet • NHS North Lancashire • Welsh Assembly Government 	<p><u>Associated Guideline Groups</u></p> <ul style="list-style-type: none"> ▪ National Clinical Guideline Centre <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> ▪ none

GE paper sign-off:

Frances Sutcliffe, Associate Director 11 June 2010

Contributors to this paper:

Information Specialist: Daniel Tuvey
 Technical Lead: Polina Vrouchou
 Technical Adviser: Helen Knight
 Project Manager: Adeola Matiluko